An interior penalty finite element method with discontinuous elements
DN Arnold - SIAM journal on numerical analysis, 1982 - SIAM
A new semidiscrete finite element method for the solution of second order nonlinear parabolic
boundary value problems is formulated and analyzed. The test and trial spaces consist of …
boundary value problems is formulated and analyzed. The test and trial spaces consist of …
PEERS: a new mixed finite element for plane elasticity
… Douglas and Milner use an analogous result to obtain interior and superconvergence estimates.
Also, Arnold … , which is analogous to an earlier result of Douglas and Roberts [9]. For this …
Also, Arnold … , which is analogous to an earlier result of Douglas and Roberts [9]. For this …
Unified analysis of discontinuous Galerkin methods for elliptic problems
We provide a framework for the analysis of a large class of discontinuous methods for
second-order elliptic problems. It allows for the understanding and comparison of most of the …
second-order elliptic problems. It allows for the understanding and comparison of most of the …
[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis
Background There is increasing evidence that B lymphocytes are involved in the pathogenesis
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …
[HTML][HTML] Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective
properties in preclinical experiments and to result in significant reductions in disease …
properties in preclinical experiments and to result in significant reductions in disease …
[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
…, A Traboulsee, JS Wolinsky, DL Arnold… - … England Journal of …, 2017 - Mass Medical Soc
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …
A stable finite element for the Stokes equations
We present in this paper a new velocity-pressure finite element for the computation of Stokes
flow. We discretize the velocity field with continuous piecewise linear functions enriched by …
flow. We discretize the velocity field with continuous piecewise linear functions enriched by …
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in
previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess …
previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess …
